TipRanks

Notifications

TSM Earnings: Taiwan Semi Rises on Q1 Beat

Taiwan Semiconductor (NYSE:TSM) shares are ticking higher today after the semiconductor major reported better-than-anticipated numbers for the first quarter.

TSM’s Q1 Results

Revenue increased by 12.9% year-over-year to $18.87 billion, outpacing expectations by $560 million. The Earnings per American Depository Receipt (EPADR) of $1.38 exceeded consensus by $0.08. However, sequentially, the company experienced declines in both its top and bottom lines.

During the quarter, TSM generated nearly 65% of its total wafer revenue from the sales of 7-nanometer and more advanced technologies. However, the company anticipates that there will be robust demand for its 3-nanometer and 5-nanometer offerings in the second quarter.

Furthermore, TSM’s CFO, Wendell Huang, stated that first-quarter results were influenced by seasonality in smartphone sale, and was partially offset by continued HPC-related demand.

TSM’S Future Outlook

Looking ahead to Q2, TSM forecasts revenue in the range of $19.6 billion to $20.4 billion, with operating profit margin expected to hover between 40% and 42%. In Q1, the company achieved an operating profit margin of 42%.

Importantly, TSM’s resilient first-quarter performance indicates increased demand for advanced chips due to the AI boom. However, investor confidence in the semiconductor sector dipped yesterday following ASML’s (NASDAQ:ASML) (DE:ASMF) weak order trends in its first-quarter results.

What Is the Target Price for TSM Stock?

TSM’s share price has rallied by nearly 60% over the past year. Overall, the Street has a Strong Buy consensus rating on the stock, alongside an average TSM price target of $154.14. However, analysts’ views on TSM could see changes following today’s earnings report.

Read full Disclosure

Kailas Salunkhe
Kailas has been writing stock news and analysis at TipRanks since 2021, and has worked in the financial domain in various roles since 2013. Prior to joining TipRanks, he served as an equity research analyst at Globflex Research, a quant fund, and Market Realist, an equity research firm, analyzing companies listed on the stock markets in the U.S., Europe, the Middle East, and Asia. Kailas has also worked as an equity trader, covering the U.S. stock markets, for Capstone Securities, a proprietary trading firm. Kailas' key strength lies in analyzing the pharmaceutical, biotech, and mining sectors and companies falling in their ambit. A proponent of long-term investing, he is also proficient in equity research, report writing, financial modeling, and pitch decks. Kailas believes that the law of compounding can work wonders for all investors if they ace the Marshmallow test.